The pharmaceutical market in egypt
Upcoming SlideShare
Loading in...5
×
 

The pharmaceutical market in egypt

on

  • 1,176 views

Understand the key pharmaceutical market characteristics, including total market size, growth drivers and resistors and overall market attractiveness....

Understand the key pharmaceutical market characteristics, including total market size, growth drivers and resistors and overall market attractiveness.
Evaluate the latest political situation and healthcare reforms and how they impact the pharmaceutical market.
Develop an understanding of the intellectual property and regulatory environment and how these can affect your product launch strategy.
Gain insight into controversial pricing issues, which have held back prices and hit profits.
Assess the major domestic and overseas pharma companies active in Egypt.

Statistics

Views

Total Views
1,176
Views on SlideShare
1,176
Embed Views
0

Actions

Likes
0
Downloads
14
Comments
0

0 Embeds 0

No embeds

Accessibility

Upload Details

Uploaded via as Adobe PDF

Usage Rights

© All Rights Reserved

Report content

Flagged as inappropriate Flag as inappropriate
Flag as inappropriate

Select your reason for flagging this presentation as inappropriate.

Cancel
  • Full Name Full Name Comment goes here.
    Are you sure you want to
    Your message goes here
    Processing…
Post Comment
Edit your comment

    The pharmaceutical market in egypt The pharmaceutical market in egypt Document Transcript

    • The Pharmaceutical Market in Egypt Buy Your Copy of Report @ http://www.reportsnreports.com/reports/169855-the- pharmaceutical-market-in-egypt.html Report Details: No. of Pages: 82 Published: June 2012 Price Single user license: US $ 3835 | Price Corporate User License: US $ 14381 The report analyzes the macroeconomic and political situation in Egypt. It covers the healthcare system, and major causes of disease and mortality. It focuses on pharmaceuticals, including their regulation, pricing, intellectual property rights, and counterfeits. It examines pharmaceutical sales, manufacturing, trade, and major multinationals and local companies. Features and benefits Understand the key pharmaceutical market characteristics, including total market size, growth drivers and resistors and overall market attractiveness. Evaluate the latest political situation and healthcare reforms and how they impact the pharmaceutical market. Develop an understanding of the intellectual property and regulatory environment and how these can affect your product launch strategy. Gain insight into controversial pricing issues, which have held back prices and hit profits. Assess the major domestic and overseas pharma companies active in Egypt. Highlights The Egyptian pharmaceutical market is focused on generics. Per capita spending is low, but the large population means overall sales are worth around $3bn. Out-of-pocket expenditure accounts for around 75% of pharmaceutical sales. In the long term, increasing affluence and universal health insurance will boost sales. Historically, intellectual property rights were not enforced, and firms were able to register generics/copies using data from the originator companies. Despite some changes, Egypt is on
    • the Watch List of the US Trade Representative due to inadequate enforcement. This means that companies have been slow to introduce new products. Egypt has certain key differences from many other markets. For example, the data protection period for drugs is five years from when the registration application is filed, rather than from the date of market authorization. Your key questions answered How is the political situation affecting pharmaceutical sales? What is the nature of research environment in Egpyt? How are the healthcare reforms going to affect the pharmaceutical market? How strictly are intellectual property rights enforced in Egypt? What are the major causes of morbidity and mortality in Egypt? Table of Contents About the author Disclaimer EXECUTIVE SUMMARY The macroeconomic climate The healthcare system and health Regulation The pharmaceutical market The macroeconomic climate Summary Introduction Country overview Economic situation Political upheaval and effect on economy The healthcare system and health Summary Introduction Healthcare expenditure The healthcare system Life expectancy Causes of death Non-communicable diseases Communicable diseases Other causes of death
    • Disease burdenNon-communicable diseasesCommunicable diseasesOther diseases and injuriesRegulationSummaryIntroductionRegulationPricingIPRCounterfeit pharmaceuticalsThe pharmaceutical marketSummaryIntroductionPharmaceutical salesMarket forecastManufacturingTradeImportsExportsDistribution networkMajor companiesMNCsRegional companiesLocal companiesAppendixScopeMethodologyGlossary/AbbreviationsBibliography/ReferencesList Of TablesTable: Ease of doing business in Egypt ranked vs. rest of world, 2011Table: Healthcare: examples of finance sources, financing agents & providersTable: Pharmaceutical sales in Egypt, 1995–2009Table: Per capita spending on pharmaceuticals in Egypt, 1995–2009Table: Egypt pharmaceutical trade in $m, 2008–10Table: HoldiPharma’s subsidiaries, percentage stake, and number of employeesTable: HoldiPharma Group sales and income, 2010–11List Of Figures
    • Figure: Population of MENA countries, 2010Figure: GNI ($bn) for top ranked MENA countries, 2009Figure: GNI ($000) per capita for top ranked MENA countries, 2009Figure: Egypt’s annual growth in GDP (%), 1980–2010Figure: Healthcare expenditure for selected countries, 2009Figure: Public health expenditure as % of total health expenditure, 2009Figure: OOP expenditure as % of private health expenditure, 2009Figure: Financing sources of Egyptian healthcare, 2007–08Figure: Financing agents of Egyptian healthcare, 2007–08Figure: Providers of Egyptian healthcare, 2007–08Figure: Life expectancy at birth for MENA countries, 2009Figure: Egyptian mortality rates per 1,000 live births, 1980–2010Figure: Egypt mortality rates for the under-fives per 1,000 live birthsFigure: Egyptian causes of death, 2008Figure: Non-communicable diseases causes of death, 2008Figure: Main causes of cardiovascular deaths, 2008Figure: Main causes of malignant neoplasm deaths, 2008Figure: Communicable diseases causes of death, 2008Figure: Egypt’s overall burden of disease by DALYs, 2004Figure: Egypt’s non-communicable diseases by DALYs, 2004Figure: Selected non-communicable diseases by DALYs, 2004Figure: Egypt’s communicable diseases by DALYs, 2004Figure: Work flow for authorization of imported branded and generic drugsFigure: Types of products registered in Egypt by source, 2011Figure: Registrations for products manufactured overseas by country, 2011Figure: Pharmaceutical sales in Egypt, 1995–2009Figure: Per capita spending on pharmaceuticals in Egypt, 1995–2009Figure: Spending on pharmaceuticals by purchaser, 2007–08Figure: MoH spending on healthcare, 2007–08Figure: Household OOP spending on healthcare, 2007–08Figure: Egypt pharmaceutical market forecast ($bn), 2012–17Figure: Imports of medicament mixtures in dosage or packaged for retail, 2010Figure: Exports of medicament mixtures in dosage or packaged for retail, 2010Figure: Pharmaceuticals registered and manufactured by MNCs in Egypt, 2011Browse more Reports @ http://www.reportsnreports.com/market-research/pharmaceuticals/Contact Us:TX, Dallas North - Dominion Plaza,17304, Preston Road,Suite 800, Dallas 75252.+ 1 888 391 5441
    • Email: sales@reportsandreports.comConnect With Us: